Bristol Myers Squibb (BMS) announced an expansion of its partnership with Sarah Cannon Research Institute (SCRI) to integrate BMS’s oncology pipeline into SCRI’s Accelero clinical trial platform.
The platform has already reduced trial startup times by 45% across eight earlier BMS studies, and the partners aim to use data-driven, community-based approaches to support faster enrollment and improve trial access for underserved groups. “By leveraging data-driven strategies through our collaboration with Sarah Cannon Research Institute, we’re working to ensure that more patients—especially those from medically underserved populations—have access to vital cancer research advances in their communities,” said Mokash Sharma, head of global development operations at BMS.
This development aligns with broader efforts to expand clinical research capacity in the region’s life sciences ecosystem.